XFOR
Bearish signalScored 2026-08-16 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
X4 Pharmaceuticals, Inc.
- Nom
- X4 Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $322.2M
- Employés
- 45
- PDG
- Adam R. Craig
- Site web
- https://www.x4pharma.com
- Marché
- ALGSFGENINMBKPTIKZRMRSN
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 47 436 titres (~210 829,30 $ US)
- Insiders
- Craig Adam R
- Total bought
-
—
Avg buy (VWAP, 90d window) $2.58 vs last close —
- Total sold
-
$353,716
Avg sell (VWAP, 90d window) $4.22 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-12
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-16 | Craig Adam R | Buy · P | 4,600 | $2.58 | $11,884 | Form 4 |
| 2026-10-01 | KIRSKE DAVID | Sell · S | 11,767 | $2.86 | $33,658 | Form 4 |
| 2026-08-12 | Craig Adam R | Sell · S | 47,436 | $4.44 | $210,829 | Form 4 |
| 2026-08-12 | Volpone John | Sell · S | 24,576 | $4.44 | $109,228 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-08-16 Drivers: fundamentals. Moteurs : fondamentaux.
XFOR presents a deeply conflicted profile: while short-term liquidity is adequate (75) and a Zacks Rank #2 upgrade provides a moderate catalyst signal (55), the fundamental health score of 25 reflects severe structural…
The first sentence of the analysis written for XFOR on 2026-08-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 10.16 · operating margin -247% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 82.2% | 68.8% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | -200.2% | -1109.6% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | -196.5% | -1078.5% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | -247.4% | -1423.6% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | -225.4% | -1452.5% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -225.6% | -1464.6% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | -225.6% | -1464.6% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -225.6% | -1464.6% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 10.156 | 3.412 | 5.340 | 5.764 | 6.267 | |
| Quick Ratio | 9.982 | 3.326 | 5.340 | 5.764 | 6.267 | |
| Solvency Ratio | -0.748 | -0.295 | -1.048 | -1.145 | -1.645 | |
| Cash Ratio | 8.427 | 1.694 | 4.340 | 5.452 | 5.832 | |
| Price To Earnings Ratio | -2.139 | -3.937 | -1.474 | -0.653 | -0.575 | |
| Price To Earnings Growth Ratio | 0.032 | 0.059 | 0.024 | 0.011 | -0.020 | |
| Forward Price To Earnings Growth Ratio | 0.032 | 0.059 | 0.024 | 0.011 | -0.020 | |
| Price To Earnings Diluted Ratio | -2.139 | -3.937 | -1.474 | -0.653 | -0.575 | |
| Price To Earnings Diluted Growth Ratio | 0.032 | 0.059 | 0.024 | 0.011 | -0.020 | |
| Price To Book Ratio | 0.908 | 6.660 | 2.918 | 0.852 | 0.915 | |
| Price To Sales Ratio | 4.818 | 57.690 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -1.909 | -1.067 | -1.544 | -0.817 | -0.824 | |
| Price To Operating Cash Flow Ratio | -1.976 | -1.127 | -1.545 | -0.818 | -0.832 | |
| Debt To Assets Ratio | 0.266 | 0.533 | 0.396 | 0.247 | 0.340 | |
| Debt To Equity Ratio | 0.415 | 3.525 | 1.141 | 0.519 | 0.618 | |
| Debt To Capital Ratio | 0.293 | 0.779 | 0.533 | 0.342 | 0.382 | |
| Long Term Debt To Capital Ratio | 0.291 | 0.773 | 0.516 | 0.304 | 0.340 | |
| Financial Leverage Ratio | 1.559 | 6.612 | 2.882 | 2.101 | 1.819 | |
| Working Capital Turnover Ratio | 0.223 | 0.029 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -3.324 | -3.982 | -4.222 | -3.454 | -5.056 | |
| Operating Cash Flow Sales Ratio | -2.438 | -51.193 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.035 | 1.056 | 1.001 | 1.001 | 1.009 | |
| Debt Service Coverage Ratio | -7.779 | -3.180 | -16.440 | -16.835 | -15.087 | |
| Interest Coverage Ratio | -9.789 | -4.152 | -18.612 | -21.931 | -20.689 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -58.633 | -37.917 | |
| Operating Cash Flow Coverage Ratio | -1.108 | -1.676 | -1.656 | -2.007 | -1.782 | |
| Capital Expenditure Coverage Ratio | -28.539 | -17.868 | -1,608.533 | -748.563 | -115.293 | |
| Dividend Paid And Capex Coverage Ratio | -28.539 | -17.868 | -1,608.533 | -748.563 | -115.293 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -0.426 | -6.161 | -1.140 | 0.226 | -0.204 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 82.2% | ▲13.4% | ▲52.0% |
| Ebit Margin | -200.2% | ▲909.4% | ▲61.8% |
| Ebitda Margin | -196.5% | ▲881.9% | ▲58.5% |
| Operating Profit Margin | -247.4% | ▲1176.1% | ▲86.8% |
| Pretax Profit Margin | -225.4% | ▲1227.0% | ▲110.1% |
| Continuous Operations Profit Margin | -225.6% | ▲1239.0% | ▲112.5% |
| Net Profit Margin | -225.6% | ▲1239.0% | ▲112.5% |
| Bottom Line Profit Margin | -225.6% | ▲1239.0% | ▲112.5% |
| Current Ratio | 10.156 | ▲6.744 | ▲3.968 |
| Quick Ratio | 9.982 | ▲6.655 | ▲3.846 |
| Solvency Ratio | -0.748 | ▼-0.453 | ▲0.228 |
| Cash Ratio | 8.427 | ▲6.733 | ▲3.278 |
| Price To Earnings Ratio | -2.139 | ▲1.798 | ▼-0.383 |
| Price To Earnings Growth Ratio | 0.032 | ▼-0.026 | ▲0.011 |
| Forward Price To Earnings Growth Ratio | 0.032 | ▼-0.026 | ▲0.011 |
| Price To Earnings Diluted Ratio | -2.139 | ▲1.798 | ▼-0.383 |
| Price To Earnings Diluted Growth Ratio | 0.032 | ▼-0.026 | ▲0.011 |
| Price To Book Ratio | 0.908 | ▼-5.752 | ▼-1.543 |
| Price To Sales Ratio | 4.818 | ▼-52.872 | ▼-7.684 |
| Price To Free Cash Flow Ratio | -1.909 | ▼-0.842 | ▼-0.677 |
| Price To Operating Cash Flow Ratio | -1.976 | ▼-0.849 | ▼-0.716 |
| Debt To Assets Ratio | 0.266 | ▼-0.267 | ▼-0.090 |
| Debt To Equity Ratio | 0.415 | ▼-3.111 | ▼-0.829 |
| Debt To Capital Ratio | 0.293 | ▼-0.486 | ▼-0.172 |
| Long Term Debt To Capital Ratio | 0.290 | ▼-0.482 | ▼-0.154 |
| Financial Leverage Ratio | 1.559 | ▼-5.053 | ▼-1.435 |
| Working Capital Turnover Ratio | 0.223 | ▲0.194 | ▲0.173 |
| Operating Cash Flow Ratio | -3.324 | ▲0.657 | ▲0.683 |
| Operating Cash Flow Sales Ratio | -2.438 | ▲48.755 | ▲8.288 |
| Free Cash Flow Operating Cash Flow Ratio | 1.035 | ▼-0.021 | ▲0.015 |
| Debt Service Coverage Ratio | -7.779 | ▼-4.598 | ▲4.085 |
| Interest Coverage Ratio | -9.789 | ▼-5.637 | ▲5.246 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲19.310 |
| Operating Cash Flow Coverage Ratio | -1.108 | ▲0.569 | ▲0.538 |
| Capital Expenditure Coverage Ratio | -28.539 | ▼-10.671 | ▲475.220 |
| Dividend Paid And Capex Coverage Ratio | -28.539 | ▼-10.671 | ▲475.220 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -0.426 | ▲5.735 | ▲1.115 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $169.2M | $147.5M | $149.1M | $63.1M | $59.0M | |
| Enterprise value | $29.4M | $169.9M | $108.2M | -$20.2M | $17.0M | |
| EV / Sales | 0.84x | 66.44x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -0.34x | -1.30x | -1.12x | 0.26x | -0.24x | |
| EV / Free cash flow | -0.33x | -1.23x | -1.12x | 0.26x | -0.24x | |
| EV / EBITDA | -0.43x | -6.16x | -1.14x | 0.23x | -0.20x | |
| Net debt / EBITDA | 2.02x | -0.81x | 0.43x | 0.93x | 0.51x | |
| Current ratio | 10.16x | 3.41x | 5.34x | 5.76x | 6.27x | |
| Income quality | 1.08x | 3.50x | 0.95x | 0.82x | 0.80x | |
| Graham net-net | $4 | -$3 | $3 | $19 | $34 | |
| Tax burden | 100.1% | 100.8% | 100.1% | 100.0% | 100.0% | |
| Interest burden | 112.6% | 130.9% | 106.1% | 104.4% | 104.3% | |
| Working capital | $235.8M | $79.3M | $99.2M | $106.4M | $73.9M | |
| Invested capital | $264.0M | $111.5M | $123.0M | $132.0M | $101.4M | |
| Return on assets | -27.3% | -25.6% | -68.7% | -60.3% | -75.7% | |
| Operating ROA | -39.8% | -24.8% | -71.0% | -64.2% | -62.8% | |
| Return on tangible assets | -30.0% | -31.4% | -77.9% | -67.9% | -88.9% | |
| Return on equity | -42.5% | -169.1% | -198.0% | -126.8% | -137.7% | |
| Return on invested capital | -32.7% | -31.7% | -85.7% | -64.5% | -71.7% | |
| Return on capital employed | -32.8% | -32.1% | -86.4% | -65.7% | -73.0% | |
| Earnings yield | -46.8% | -25.4% | -67.8% | -148.8% | -150.4% | |
| Free cash flow yield | -52.4% | -93.7% | -64.8% | -122.4% | -121.3% | |
| Capex / Op. cash flow | -3.5% | -5.6% | -0.1% | -0.1% | -0.9% | |
| Capex / Depreciation | 234.9% | 920.4% | 14.3% | 20.1% | 32.5% | |
| Capex / Sales | 8.5% | 286.5% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 123.9% | 2405.9% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 205.7% | 3192.9% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 12.2% | 320.8% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 9.2% | 18.7% | 11.8% | 11.2% | 14.8% | |
| Days sales outstanding | 6d | 244d | 0d | 0d | 0d | |
| Days payables outstanding | 332d | 3948d | 0d | 0d | 826d | |
| Operating cycle | 267d | 1534d | 0d | 0d | 0d | |
| Cash conversion cycle | -65d | -2414d | 0d | 0d | -826d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-11 X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here''s Why X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 2026-08-06 X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the second quarter ended June 30, 2026 and provided a corporate update.
- 2026-08-03 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 12,000 shares of X4''s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4''s Compensation Committee of the Board of Directors.
- 2026-07-07 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 6, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 750,000 shares of X4''s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4''s Compensation Committee of the Board of Directors.
- 2026-07-01 X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the Company''s Board of Directors effective July 1, 2026, adding strong strategic and financial expertise. Ms. Gold will serve as an independent director and member of the Audit Committee.
- 2026-06-01 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on May 29, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 160,000 shares of X4''s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4''s Compensation Committee of the Board of Directors.
- 2026-05-27 X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 3:45 p.m. ET. A link to the live and archived webcast may be accessed on X4 Pharmaceuticals'' website under the Investors section: Events and Presentations.
- 2026-05-20 Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here''s Why It''s a ''Buy'' Now X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 2026-05-18 X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here''s What You Should Know X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).